MedinCell S.A. (0ACH.L)

14,00 -0,96 (-6,42%) Alla chiusura: 01:25PM BST

MedinCell S.A.

3 rue des FrEres LumiEre
Jacou 34830
France
33 4 67 02 13 67
https://www.medincell.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 138

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Christophe Douat	CEO & Chairman of Executive Board	392,77k	N/D	1966
Mr. Franck Pouzache	Chief People Officer & Member of the Management Board	198,89k	N/D	N/D
Stephane Postic	Chief Financial Officer	N/D	N/D	N/D
Julie Alimi	Head of Legal	N/D	N/D	N/D
Mr. David Heuze	Head of Communications	N/D	N/D	N/D
Mr. Adolfo Lopez-Noriega	Head of Research & Development	N/D	N/D	N/D
Mr. Sebastien Enault	Chief Business Officer	N/D	N/D	N/D
Ms. Helen Martin	Head of Alliance & Project Management	N/D	N/D	N/D
Ms. Quiterie De Beauregard	Head of Global Health Development	N/D	N/D	N/D
Dr. Richard Malamut M.D.	Chief Medical Officer	N/D	N/D	1960

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology. The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension for use in the treatment of schizophrenia in adults; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for organ transplant; mdc-WWM for contraception; mdc-STM for malaria; and mdc-IRM for neuroscience. MedinCell S.A. was incorporated in 2003 and is based in Jacou, France.

Governance aziendale

L'ISS Governance QualityScore di MedinCell S.A. al 1 maggio 2024 è 9. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 8; diritti degli azionisti: 9; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.